T2 BIOSYSTEMS,INC. (NASDAQ:TTOO) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
On December 22, 2017, T2 Biosystems, Inc. (the “Company”) and SMC,Ltd. (the “Supplier”) entered into a Second Amendment to Supply Agreement (the “Amendment”), amending that certain Supply Agreement, dated as of October10, 2014 (the “Supply Agreement”) and previously amended on August29, 2017.
The Amendment extends the term of the Supply Agreement from December31, 2017 to March31, 2018.
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit10.1 to this Current Report on Form8-K and is incorporated herein by reference.
|Item 1.01||Financial Statements and Exhibits|
T2 Biosystems, Inc. ExhibitEX-10.1 2 d496730dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SECOND AMENDMENT TO SUPPLY AGREEMENT This SECOND AMENDMENT TO SUPPLY AGREEMENT (Amendment) is entered into on December 22,…To view the full exhibit click
About T2 BIOSYSTEMS,INC. (NASDAQ:TTOO)
T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.